Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Affymetrix_miRNA4.0

ABSTRACT: Primary renal cell carcinoma (RCC) by Affymetrix GeneChip miRNA 4.0

PROVIDER: EGAD00010001564 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes.

Winter Stefan S Fisel Pascale P Büttner Florian F Rausch Steffen S D'Amico Debora D Hennenlotter Jörg J Kruck Stephan S Nies Anne T AT Stenzl Arnulf A Junker Kerstin K Scharpf Marcus M Hofmann Ute U van der Kuip Heiko H Fend Falko F Ott German G Agaimy Abbas A Hartmann Arndt A Bedke Jens J Schwab Matthias M Schaeffeler Elke E

Scientific reports 20160720

Current therapies for metastatic clear cell renal cell carcinoma (ccRCC) show limited efficacy. Drug efficacy, typically investigated in preclinical cell line models during drug development, is influenced by pharmacogenes involved in targeting and disposition of drugs. Here we show through genome-wide DNA methylation profiling, that methylation patterns are concordant between primary ccRCC and macro-metastases irrespective of metastatic sites (rs ≥ 0.92). However, 195,038 (41%) of all investigat ...[more]

PMID: 27435027

Similar Datasets

Affymetrix_HTA2.0

Project description:Primary renal cell carcinoma (RCC) and RCC metastases by Affymetrix GeneChip HTA 2.0

| EGAD00010001589 | EGA

microRNA Profiling in Metastatic Renal Cell Carcinoma

Project description:We performed a microRNA (miRNA) microarray on 10 metastatic RCC tumors and compared differential miRNA expresison to 19 primary clear cell renal cell carcinomas (ccRCC). We found there were 65 significantly dysregulated miRNAs; 9 miRNAs were significantly upregulated and 56 miRNAs were significantly downregulated in metastatic RCC when compared to primary clear cell renal cell carcinoma.

2012-08-14 | GSE39440 | GEO

microRNA Profiling in Metastatic Renal Cell Carcinoma

2012-08-13 | E-GEOD-39440 | biostudies-arrayexpress

Expression data of cDNA from the ACHN control and Kindlin-2-depleting cells

Project description:Kindlin-2, an integrin-interacting FERM-domain-containing protein, has been known to play critical roles for tumor progression. However, the role of Kindlin-2 in renal cell carcinoma (RCC) progression has not been reported. We aim to investigate the role of Kindlin-2 in the progression of RCC and the underlying mechanisms. To uncover the related pathway in which Kindlin-2 is involved to promote clear cell renal cell carcinoma progression, ACHN control and Kindlin-2-depleting cells were analyzed by Affymetrix GeneChip human Gene 1.0 ST Arrays.

2015-12-16 | GSE76020 | GEO

microRNA profiling in renal cell carcinoma subtypes

Project description:Renal cell carcinoma is the most common neoplasm of the adult kidney. A few subtypes of RCC include papillary RCC (pRCC), chromophobe RCC (chRCC) and the benign oncocytoma tumor. In some cases, distinguishing between the RCC subyptes is difficult. We performed a mircroRNA (miRNA) microarray to determine differential miRNA expression between pRCC, chRCC, and oncocytoma. We performed a miRNA microarray on 10 tumor samples of each papillary renal cell carcinoma (pRCC), chromophobe renal cell carcinoma (chRCC), and oncocytoma.

2012-08-13 | E-GEOD-39790 | biostudies-arrayexpress

miRNA expression of papillary renal neoplasm with reverse polarity (PRNRP) cases

Project description:Between 80% and 90% of renal carcinomas are either clear cell renal cell carcinoma or papillary RCC although there are at least 20 other distinct forms of RCC recognised by the World Health Organization (WHO). Emerging or provisional entities have been considered as variants of PRCC, including papillary renal neoplasm with reversed polarity (PRNRP). However, the molecular basis of PRNRP, and miRNA expression profile, is unknown. We used microarray analysis to elucidate the non-coding RNA (ncRNA) profiles of 10 PRNRP cases and compared them with other renal neoplasms. Cases were only considered for this study after fulfilment of strict inclusive histological and immunohistochemical criteria. We used Affymetrix miRNA v.4.0 arrays to elucidate the expression of these samples.

2024-02-18 | GSE255707 | GEO

Genotyping and copy number analysis of human renal epithelial neoplasms

Project description:Renal tumors with complex morphology require extensive workup for accurate classification. Chromosomal aberrations that define subtypes of renal epithelial neoplasms have been reported. We explored if whole-genome chromosome copy number and loss-of-heterozygosity analysis with single nucleotide polymorphism (SNP) arrays can be used to identify these aberrations. Experiment Overall Design: We analyzed 20 paraffin-embedded tissues representing conventional renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, and oncocytoma with Affymetrix GeneChip 10K 2.0 Mapping arrays.

2008-04-10 | E-GEOD-9469 | biostudies-arrayexpress

microRNA profiling in renal cell carcinoma subtypes

2012-08-14 | GSE39790 | GEO

dePillis2013 - Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment

Project description:Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment Lisette dePillis 1, , Trevor Caldwell 2, , Elizabeth Sarapata 2, and Heather Williams 2, 1. Department of Mathematics, Harvey Mudd College, Claremont, CA 91711 2. Harvey Mudd College, Claremont, CA 91711, United States, United States, United States Abstract We present a mathematical model to study the effects of the regulatory T cells (Treg) on Renal Cell Carcinoma (RCC) treatment with sunitinib. The drug sunitinib inhibits the natural self-regulation of the immune system, allowing the effector components of the immune system to function for longer periods of time. This mathematical model builds upon our non-linear ODE model by de Pillis et al. (2009) [13] to incorporate sunitinib treatment, regulatory T cell dynamics, and RCC-specific parameters. The model also elucidates the roles of certain RCC-specific parameters in determining key differences between in silico patients whose immune profiles allowed them to respond well to sunitinib treatment, and those whose profiles did not. Simulations from our model are able to produce results that reflect clinical outcomes to sunitinib treatment such as: (1) sunitinib treatments following standard protocols led to improved tumor control (over no treatment) in about 40% of patients; (2) sunitinib treatments at double the standard dose led to a greater response rate in about 15% the patient population; (3) simulations of patient response indicated improved responses to sunitinib treatment when the patient's immune strength scaling and the immune system strength coefficients parameters were low, allowing for a slightly stronger natural immune response. Keywords: Renal cell carcinoma, mathematical modeling., sunitinib, immune system, regulatory T cells.

2020-01-06 | BIOMD0000000908 | BioModels

Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumors in patients

Project description:Development of a clinically relevant animal models of RCC for preclinical investigations. For DNA copy number analysis, the Sty I (250K) SNP array of the 500K Human Mapping Array (Affymetrix) was used. Arrays were scanned by GeneChip Scanner 3000 7G. Probe-level signal intensities were normalized to a baseline array with median intensity using invariant set normalization and SNP-level signal intensities were obtained using a model-based (PM/MM) method. Keywords: SNP array data, renal cell carcinoma

2011-05-05 | GSE29062 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data